We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study.
- Authors
J.N. Hugues; J. Soussis; I. Calderon; J. Balasch; R.A. Anderson; A. Romeu
- Abstract
BACKGROUND: In anovulatory women undergoing ovulation induction, addition of recombinant human LH (rLH) to FSH treatment may promote the dominance of a leading follicle when administered in the late follicular phase. The objective of this study was to find the optimal dose of rLH that can maintain the growth of a dominant follicle, whilst causing atresia of secondary follicles. METHODS: Women with infertility due to anovulation and over-responding to FSH treatment were randomized to receive, in addition to 37.5?IU recombinant human FSH (rFSH), either placebo or different doses of rLH (6.8, 13.6, 30 or 60?g) daily for a maximum of 7 days. The primary efficacy endpoint was the proportion of patients who had exactly one follicle =16?mm on hCG day. RESULTS: Among 153 enrolled patients, the five treatment groups were similar in terms of baseline characteristics. The proportion of patients with exactly one follicle =16?mm ranged from 13.3% in the placebo group to 32.1% in the 30?g rLH group (P=0.048). The pregnancy rate ranged from 10.3% in the 60?g group to 28.6% in the 30?g rLH group. Adverse events were similar between groups. CONCLUSIONS: In patients over-responding to FSH during ovulation induction, doses of up to 30?g rLH/day appear to increase the proportion of patients developing a single dominant follicle (=16?mm). Our data support the LH ceiling concept whereby addition of rLH is able to control development of the follicular cohort.
- Subjects
ANOVULATION; REPRODUCTION; PROPORTION; CORPUS luteum
- Publication
Human Reproduction, 2005, Vol 20, Issue 3, p629
- ISSN
0268-1161
- Publication type
Article
- DOI
10.1093/humrep/deh682